SCHEMBL4715745

SCHEMBL4715745

COc1cc2c(cc1OC)C(=O)CN(S(=O)(=O)c1ccc(C)cc1)C2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 4/20 0.52
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
LMNA P02545 3/20 0.47
RYR2 Q92736 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
KCNN4 O15554 1/20 0.45
KCNA3 P22001 1/20 0.45
PDE4B Q07343 2/20 0.44
PDE4D Q08499 1/20 0.44
GAA P10253 3/20 0.44
ALDH1A1 P00352 3/20 0.44
ATM Q13315 1/20 0.44
MCOLN3 Q8TDD5 1/20 0.44
USP2 O75604 1/20 0.44
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17137356 0.91 ALDH1A1 (0.51) PKMKMT2AMEN1LMNARYR2
SCHEMBL9602776 0.88 PKM (0.64) PKMKMT2AMEN1LMNARYR2
SCHEMBL21315085 0.82 KCNN4 (0.47) PKMKMT2AMEN1RYR2CYP2C19
SCHEMBL16858557 0.79 KCNN4 (0.38) PKMKMT2AMEN1RYR2SMN1; SMN2
SCHEMBL25422392 0.78 HDAC1 (0.46) PKMKMT2AMEN1RYR2CYP2C19
SCHEMBL13171923 0.78 KCNN4 (0.46) PKMKMT2AMEN1RYR2CYP2C19
SCHEMBL16858559 0.78 KCNN4 (0.43) PKMKMT2AMEN1LMNARYR2
SCHEMBL3680871 0.77 KCNN4 (0.60) PKMKMT2ALMNASMN1; SMN2KCNN4
SCHEMBL4044050 0.76 RYR2 (0.57) PKMKMT2ALMNARYR2SMN1; SMN2
SCHEMBL11773546 0.75 PKM (0.61) PKMKMT2AMEN1LMNARYR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996574-A1 QUINOLINE AND ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-12-03 EP disclosed
US-20070299067-A1 Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors AMGEN INC. 2007-12-27 US disclosed
WO-2007103554-A1 QUINOLINE AND ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299067-A1 Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors PDE12, PDE10A, PDE4A PKM 3139/4885KMT2A 2094/4885MEN1 2743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.